| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:52:00 UTC |
|---|
| HMDB ID | HMDB0015509 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Ethylmorphine |
|---|
| Description | Ethylmorphine, also known as dionine or trachyl, belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic. Morphine interacts predominantly with the opioid mu-receptor. Ethylmorphine is a very strong basic compound (based on its pKa). In humans, ethylmorphine is involved in ethylmorphine action pathway. It is not marketed in the US but is approved for use in various countries around the world. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. |
|---|
| Structure | [H][C@@]12OC3=C(OCC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| Dionine | HMDB | | Ethyl morphine | HMDB | | Ethylmorphine, (5alpha,6beta)-isomer | HMDB | | Novartis brand OF ethylmorphine hydrochloride, (5alpha,6alpha)-isomer | HMDB | | Trachyl | HMDB | | Ethomorphine | HMDB | | Ethylmorphine hydrochloride, (5alpha,6alpha)-isomer | HMDB | | Ethylmorphine sulfate (2:1), (5alpha,6alpha)-isomer | HMDB | | Ethylmorphine hydrochloride, dihydrate, (5alpha,6alpha)-isomer | HMDB |
|
|---|
| Chemical Formula | C19H23NO3 |
|---|
| Average Molecular Weight | 313.3908 |
|---|
| Monoisotopic Molecular Weight | 313.167793607 |
|---|
| IUPAC Name | (1S,5R,13R,14S,17R)-10-ethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraen-14-ol |
|---|
| Traditional Name | ethylmorphine |
|---|
| CAS Registry Number | 76-58-4 |
|---|
| SMILES | [H][C@@]12OC3=C(OCC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O |
|---|
| InChI Identifier | InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1 |
|---|
| InChI Key | OGDVEMNWJVYAJL-LEPYJNQMSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Alkaloids and derivatives |
|---|
| Class | Morphinans |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Morphinans |
|---|
| Alternative Parents | |
|---|
| Substituents | - Morphinan
- Phenanthrene
- Tetralin
- Coumaran
- Alkyl aryl ether
- Aralkylamine
- Piperidine
- Benzenoid
- Secondary alcohol
- Tertiary amine
- Tertiary aliphatic amine
- Ether
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Organopnictogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Alcohol
- Hydrocarbon derivative
- Organic nitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 199 - 201 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.84 g/L | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.24 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.3972 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.07 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 92.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1281.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 201.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 145.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 172.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 73.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 297.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 322.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 488.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 813.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 313.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1031.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 222.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 248.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 386.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 414.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 27.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Ethylmorphine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0671-1090000000-ee6bb48baf50c5f0670d | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ethylmorphine GC-MS (1 TMS) - 70eV, Positive | splash10-00fr-8019000000-beb618b0f58f701fb24e | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ethylmorphine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ethylmorphine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 10V, Positive-QTOF | splash10-03di-0049000000-e64f6928d31bc2f5e107 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 20V, Positive-QTOF | splash10-03di-1095000000-59a9dd24e82a0c7408b8 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 40V, Positive-QTOF | splash10-0pvi-2090000000-b870f6f4d523dfc80ab1 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 10V, Negative-QTOF | splash10-03di-0029000000-34c8963f215272a01a9b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 20V, Negative-QTOF | splash10-03e9-1095000000-566ee946086b9b47cb7a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 40V, Negative-QTOF | splash10-00os-2090000000-2f55fa4e64af44c96a21 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 10V, Positive-QTOF | splash10-03di-0009000000-879645690cd5fc806db2 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 20V, Positive-QTOF | splash10-03di-0049000000-f058a1d6993a96cbdcbe | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 40V, Positive-QTOF | splash10-0k92-0091000000-89c269fb29eb1ca16959 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 10V, Negative-QTOF | splash10-03di-0009000000-19200665d806a98057c5 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 20V, Negative-QTOF | splash10-03di-0039000000-ded7c070e5e8b4cb3500 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ethylmorphine 40V, Negative-QTOF | splash10-001i-0091000000-7a013b74465d3642aeaa | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Aasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjorneboe A, Christophersen AS, Bodd E, Morland J: Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20. [PubMed:7654478 ]
- Xu BQ, Aasmundstad TA, Lillekjendlie B, Bjorneboe A, Christophersen AS, Morland J: Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model. Pharmacol Toxicol. 1997 Apr;80(4):171-81. [PubMed:9140136 ]
|
|---|